Sponsors (2)
The bill aims to speed patient access to biosimilars and reduce inspection delays by expanding mutual recognition and remote tools and clarifying regulatory roles, but it increases oversight reliance on non‑U.S. partners and remote assessments, creating potential safety, legal, cost, and data‑privacy risks that must be managed.
Patients with chronic conditions could get faster access to biosimilar medicines because FDA would target inspections by risk, expand reliance on mutual recognition/remote assessments, and resolve inspection issues earlier in review.
Hospitals, health systems, and biologic manufacturers could face fewer duplicate inspections and shorter regulatory delays because FDA may rely more on trusted foreign partners, remote assessments, and clearer inspection expectations.
Manufacturers, suppliers, and federal regulators get clearer regulatory rules because the bill defines covered products/establishments and ties the 'Secretary' role to action through the FDA Commissioner, reducing ambiguity about compliance and enforcement responsibility.
Patients and health systems could face increased drug-quality or safety risks if greater reliance on foreign MRAs or remote inspections creates gaps in oversight or misses issues that on-site inspections would catch.
Taxpayers, FDA, and manufacturers could incur substantial upfront administrative, training, and IT costs to build, coordinate, and implement expanded MRA programs and remote inspection systems.
Hospitals, small manufacturers, and other stakeholders could face legal uncertainty or litigation risk because the bill ties 'establishment' to a specific statutory subsection (a cross-reference that may be ambiguous or nonexistent).
Based on analysis of 5 sections of legislative text.
Requires FDA to expand use of mutual recognition agreements and remote assessments, update risk-based inspection processes for biosimilar makers, hold a public meeting, and publish a one-year strategic plan.
Introduced December 16, 2025 by Theodore Paul Budd · Last progress December 16, 2025
Requires the Department of Health and Human Services (through FDA) to modernize how it inspects establishments that make biosimilar biological products. The agency must hold a public meeting about using mutual recognition agreements (MRAs) for inspections, issue a follow-up report with recommendations, expand use of remote regulatory assessments and other alternative inspection tools, and publish a one-year strategic plan addressing staffing, inspection challenges, and communication with biosimilar sponsors.